Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 7
2000 4
2001 2
2002 2
2003 3
2004 2
2006 4
2007 2
2009 2
2010 2
2012 1
2013 2
2014 1
2015 3
2017 1
2018 1
2020 1
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

40 results
Results by year
Filters applied: . Clear all
Page 1
Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19).
Lièvre A, Turpin A, Ray-Coquard I, Le Malicot K, Thariat J, Ahle G, Neuzillet C, Paoletti X, Bouché O, Aldabbagh K, Michel P, Debieuvre D, Canellas A, Wislez M, Laurent L, Mabro M, Colle R, Hardy-Bessard AC, Mansi L, Colomba E, Bourhis J, Gorphe P, Pointreau Y, Idbaih A, Ursu R, Di Stefano AL, Zalcman G, Aparicio T; GCO-002 CACOVID-19 collaborators/investigators. Lièvre A, et al. Among authors: mabro m. Eur J Cancer. 2020 Dec;141:62-81. doi: 10.1016/j.ejca.2020.09.035. Epub 2020 Oct 8. Eur J Cancer. 2020. PMID: 33129039 Free PMC article.
Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.
André T, Vernerey D, Mineur L, Bennouna J, Desrame J, Faroux R, Fratte S, Hug de Larauze M, Paget-Bailly S, Chibaudel B, Bez J, Dauba J, Louvet C, Lepere C, Dupuis O, Becouarn Y, Mabro M, Egreteau J, Bouche O, Deplanque G, Ychou M, Galais MP, Ghiringhelli F, Dourthe LM, Bachet JB, Khalil A, Bonnetain F, de Gramont A, Taieb J; for PRODIGE investigators, GERCOR, Fédération Française de Cancérologie Digestive, and UNICANCER. André T, et al. Among authors: mabro m. J Clin Oncol. 2018 May 20;36(15):1469-1477. doi: 10.1200/JCO.2017.76.0355. Epub 2018 Apr 5. J Clin Oncol. 2018. PMID: 29620995 Clinical Trial.
[Aspirin against cancer].
Mabro M, de Gramont A. Mabro M, et al. Rev Med Interne. 2000 Mar;21 Suppl 1:60s-67s. doi: 10.1016/s0248-8663(00)88726-3. Rev Med Interne. 2000. PMID: 10763206 Review. French.
Prognostic factors of colorectal cancer patients with brain metastases.
Roussille P, Auvray M, Vansteene D, Lecomte T, Rigault E, Maillet M, Locher C, Dior M, Hautefeuille V, Artru P, Mabro M, Touchefeu Y, Marthey L, Moulin V, Louafi S, Lecaille C, Chautard R, Lièvre A, Zaanan A, Bennouna J, Berger A, Emambux S, Randrian V, Tougeron D. Roussille P, et al. Among authors: mabro m. Radiother Oncol. 2021 May;158:67-73. doi: 10.1016/j.radonc.2021.02.006. Epub 2021 Feb 16. Radiother Oncol. 2021. PMID: 33600872
Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.
Bidard FC, Tournigand C, André T, Mabro M, Figer A, Cervantes A, Lledo G, Bengrine-Lefevre L, Maindrault-Goebel F, Louvet C, de Gramont A. Bidard FC, et al. Among authors: mabro m. Ann Oncol. 2009 Jun;20(6):1042-7. doi: 10.1093/annonc/mdn730. Epub 2009 Jan 19. Ann Oncol. 2009. PMID: 19153116 Free article. Clinical Trial.
Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study.
Palle J, Tougeron D, Pozet A, Soularue E, Artru P, Leroy F, Dubreuil O, Sarabi M, Williet N, Manfredi S, Martin-Babau J, Rebischung C, Abdelghani MB, Evesque L, Dreanic J, Hautefeuille V, Louafi S, Sefrioui D, Savinelli F, Mabro M, Rousseau B, Lecaille C, Bouché O, Louvet C, Lecomte T, Bonnetain F, Taieb J, Zaanan A. Palle J, et al. Among authors: mabro m. Oncotarget. 2017 Sep 8;8(60):101383-101393. doi: 10.18632/oncotarget.20711. eCollection 2017 Nov 24. Oncotarget. 2017. PMID: 29254172 Free PMC article.
Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study).
Hebbar M, Tournigand C, Lledo G, Mabro M, André T, Louvet C, Aparicio T, Flesch M, Varette C, de Gramont A; Oncology Multidisciplinary Research Group (GERCOR). Hebbar M, et al. Among authors: mabro m. Cancer Invest. 2006 Mar;24(2):154-9. doi: 10.1080/07357900500524397. Cancer Invest. 2006. PMID: 16537184 Clinical Trial.
Prognostic value and relation with adjuvant treatment duration of ctDNA in stage III colon cancer: a post-hoc analysis of the PRODIGE-GERCOR IDEA-France trial.
Taieb J, Taly V, Henriques J, Bourreau C, Mineur L, Bennouna J, Desrame J, Louvet C, Lepere C, Mabro M, Egreteau J, Bouche O, Mulot C, Hormigos K, Chaba K, Mazard T, de Gramont A, Vernerey D, André T, Laurent-Puig P. Taieb J, et al. Among authors: mabro m. Clin Cancer Res. 2021 Jun 3:clincanres.0271.2021. doi: 10.1158/1078-0432.CCR-21-0271. Online ahead of print. Clin Cancer Res. 2021. PMID: 34083233
[Primary hyperparathyroidism associated with colon cancer].
Artru P, Tournigand C, Mabro M, Lucchi E, Louvet C, De Gramont A, Krulik M. Artru P, et al. Among authors: mabro m. Gastroenterol Clin Biol. 2001 Feb;25(2):208-9. Gastroenterol Clin Biol. 2001. PMID: 11319452 Free article. French. No abstract available.
40 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page